As we all navigate uncharted territory during this COVID-19 epidemic, La Jolla Institute for Immunology is committed to updating the community on its related research efforts underway as well as resources for additional information.
Live from the Lab with LJI’s New President & CEO Erica Ollmann Saphire, Ph.D.
On September 21, 2021, La Jolla Institute for Immunology’s (LJI’s) newly appointed President and Chief Executive Officer Dr. Erica Ollmann Saphire shared her vision for the Institute’s future and provided her perspective on where the world stands with COVID-19. Expert insights during the virtual discussion were provided by the Institute’s Chief Scientific Officer Mitchell Kronenberg, Ph.D. Technical expertise was shared during the lab component of the presentation by Saphire Laboratory Program Manager Sharon Schendel, Ph.D., who has been the boots on the ground with the Coronavirus Immunotherapy Consortium (CoVIC), which Dr. Saphire is leading and which was highlighted in this presentation. CoVIC is a global, academic-industry, non-profit research collaboration that brings together scientists from around the world to understand which antibodies are most effective against the novel coronavirus SARS-CoV-2, and to streamline and accelerate the research pipeline for antibody-based therapeutics needed against SARS-CoV-2.